Appendix

Clinical Trials

INTERVENTIONAL NEURORADIOLOGY HUMANITARIAN USE DEVICES (HUDS)


Dr. Michael Brant-Zawadzki, Principal Investigator: Boston Scientific Target Neuroform™ Microdelivery Stent System and Neuroform EZ Stent System for Cerebral Aneurysm (H020002).


Dr. Wallace Peck, Principal Investigator: Stryker Corporation Wingspan™ Stent System with Gateway™ PTA Balloon Catheter for Cerebral Aneurysm (H050001).


Dr. Wallace Peck, Principal Investigator: MicroVention Lowprofile Visualized Intraluminal Support (LVIS®) or LVIS Jr. Humanitarian Use Device (“LVIS HUD”) for Cerebral Aneurysm.


STROKE CLINICAL RESEARCH


Dr. David Brown, Principal Investigator: Sleep SMART “Sleep for Stroke Management And Recovery Trial: Phase 3 Multicenter, Prospective Randomized Open-, Blinded-Endpoint (PROBE) Controlled Trial To Test Whether Treatment Of Obstructive Sleep Apnea (OSA) With Continuous Positive Airway Pressure Is Effective For Secondary Prevention And Recovery After Stroke.” Funded By NINDS.

ALZHEIMER’S DISEASE CLINICAL RESEARCH


Dr. William Shankle, Principal Investigator: F. Hoffman-La Roche Protocol BN29552 “CREAD”: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer’s Disease.


Dr. William Shankle, Principal Investigator: F. Hoffman-La Roche Protocol BN40031: A Multicenter, Open-Label, Long- Term Extension Of Phase III Studies (BN29552/BN29553) Of Crenezumab In Patients With Alzheimer’s Disease.


Dr. William Shankle, Principal Investigator: Biogen 221AD302 “EMERGE”: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer’s Disease.


Dr. William Shankle, Principal Investigator: Eli Lilly Protocol I5T-MC-AACG “TRAILBLAZER-ALZ”Assessment of Safety, Tolerability and Efficacy of LY3002813 Alone and in Combination with LY3202626 in Early Symptomatic Alzheimer’s Disease.


Dr. William Shankle, Principal Investigator: Biogen 251AD201 “TANGO” - “Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer’s Disease or with Mild Alzheimer’s Disease”.


Dr. William Shankle, Principal Investigator: COCOA: Coaching for Cognition in Alzheimer’s Disease.


Doctor